What determines HACE1's transition from tumor suppressor to neurodegeneration mediator?

OPEN

The abstract presents a contradiction where HACE1 is inactive/protective in tumors but actively contributes to neurodegeneration pathology. The molecular mechanisms governing this context-dependent functional switch remain unexplained, limiting therapeutic targeting strategies. Gap type: contradiction Source paper: Emerging role and mechanism of HACE1 in the pathogenesis of neurodegenerative diseases: A promising target. (2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, PMID:38364733)

Priority: 0.76 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What determines HACE1's transition from tumor suppressor to neurodegeneration mediator? is a 0.76 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What determines HACE1's transition from tumor suppressor to neurodegeneration mediator? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (3)

HACE1Alzheimer's diseaseHACE1Parkinson's diseaseHACE1Huntington's disease

interacts with (3)

HACE1OPTNHACE1RAC1HACE1NFE2L2

regulates (2)

HACE1autophagyHACE1oxidative stress
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps